Table 3:
Imaging Findings—Associations with Enrollment Characteristics and Outcomes
| Image Findings | Enrollment characteristics | |
|---|---|---|
|
| ||
| Atrophy | cART at enrollment | OR 2.1 (95% CI 0.6 to 7.6) |
| EFV use | OR 0.2 (95% CI 0.02 to 1.2) | |
| Seizure z severity (1=single, brief) | ||
| Multiple, prolonged | OR 0.6 (95% CI 0.1 to 3.0) | |
| Status Epilepticus | OR 0.5 (95% CI 0.1 to 2.6) | |
| WHO stage (1= Stage I) | ||
| WHO Stage II | OR 3.0 (95% CI 0.2to 43.7) | |
| WHO Stage III | OR 15.0 (95% CI 0.4 to 576.7) | |
| WHO Stage IV | OR 7.2 (95% CI 1.1 to 48.3) | |
| CDC stage (1=Stage 1) | ||
| Stage 2 | OR 1.2 (95% CI 0.1 to 11.9) | |
| Stage 3 | OR 8.3 (95% CI 1.2 to 59.3) | |
|
| ||
| Focal structural abnormality | cART at enrollment | OR 0.22 (95% CI 0.05 to 1.0) |
| EFV use | OR 10.8 (95% CI 1.0 to 117.0) | |
| Seizure severity (1=single, brief) | ||
| Multiple, prolonged | OR 1.6 (95% CI 0.2 to 13.9) | |
| Status Epilepticus | OR 0.1 (95% CI 0.0 to 0.90) | |
| WHO stage (1=Stage I) | ||
| WHO Stage II | OR 0.3 (95% CI 0.0 to 4.9) | |
| WHO Stage III | OR 0.6 (95% CI 0.0 to 23.1) | |
| WHO Stage IV | OR 0.3 (95% CI 0.0 to 1.9) | |
| CDC stage (1=Stage 1) | ||
| Stage 2 | OR 0.4 (95% CI 0.0 to 4.0) | |
| Stage 3 | OR 0.5 (95% CI 0.1 to 3.4) | |
|
| ||
| Subcortical white matter abnormality | cART at enrollment | OR 0.4 (95% CI 0.1 to 1.5) |
| EFV use | OR 1.0 (95% CI 0.1 to 7.5) | |
| Seizure severity (1=single, brief) | ||
| Multiple, prolonged | OR 2.3 (95%CI 0.4 to 11.5) | |
| Status Epilepticus | OR 0.3 (95% CI 0.0 to 1.8) | |
| WHO stage (1=Stage I) | ||
| WHO Stage II | OR 0.6 (95% CI 0.1 to 6.7) | |
| WHO Stage III | OR 0.3 (95% CI 0.01 to 10.6) | |
| WHO Stage IV | OR 0.6 (95% CI 0.1 to 2.7) | |
| CDC stage (1=Stage 1) | ||
| Stage 2 | OR 0.5 (95% CI 0.03 to 7.1) | |
| Stage 3 | OR 2.0 (95% CI 0.3 to 13.4) | |
|
| ||
| Leptomeningeal enhancement | cART at enrollment | OR 1.2 (95% CI 0.2 to 6.1) |
| EFV use | OR 2.4 (95% CI 0.3 to 22.1) | |
| Seizure severity (1=single, brief) | ||
| Multiple, prolonged | OR 4.5 (95% CI 0.4 to 46.2) | |
| Status Epilepticus | OR 0.7 (95% CI 0.03 to 12.6) | |
| WHO stage (1=Stage I) | ||
| WHO Stage 2 | OR 0.6 (95% CI 0.1 to 6.7) | |
| WHO Stage 3 | OR 0.3 (95% CI 0.0 to 10.6) | |
| WHO Stage 4 | OR 0.1 (95% CI 0.0 to 0.6) | |
| CDC stage (1=Stage 1) | ||
| Stage 2 | OR 0.7 (95% CI 0.1 to 5.9) | |
| Stage 3 | OR 0.1 (95% CI 0.0 to 1.4) | |
|
| ||
| Imaging Finding | Outcomes | |
|
| ||
| Atrophy | Recurrent seizure(s) | OR 1.4 (95% CI 0.4 to 5.2) |
| Neurocognitive impairment | OR 8.4 (95% CI 1.3 to 55.4) | |
| Death | OR 1.4 (95% CI 0.4 to 4.9) | |
|
| ||
| Focal structural abnormality | Recurrent seizure(s) | OR 0.4 (95% CI 0.1 to 1.7) |
| Neurocognitive impairment | OR 0.2 (95% CI 0.03 to 0.90) | |
| Death | OR 1.7 (95% CI 0.4 to 6.8) | |
|
| ||
| Subcortical white matter abnormality | Recurrent seizure(s) | OR 0.4 (95% CI 0.1 to 1.6) |
| Neurocognitive impairment | OR 0.4 (95% CI 0.1 to 2.6) | |
| Death | OR 1.8 (95% CI 0.5 to 6.6) | |
|
| ||
| CVA (any age infarct) | Recurrent seizure(s) | OR 2.0 (95% CI 0.3 to 13.6) |
| Death | OR 0.3 (95% CI 0.03 to 2.4) | |
|
| ||
| Leptomeningeal abnormality | Recurrent seizure(s) | OR 0.3 (95% CI 0.03 to 2.6) |
| Neurocognitive impairment | OR 0.6 (95% CI 0.05 to 6.6) | |
| Death | OR 0.6 (95% CI 0.1 to 3.5) | |
Bolded categories represent results with P value p<0.05.